Venus Remedies, a Chandigarh-based company, has secured market authorization in the UK for Bleomycin 15,000 IU powder for injection or infusion, with distribution handled by their German subsidiary, Venus Pharma GmbH.

Bleomycin 15,000 IU is a potent medication that contains bleomycin sulfate as its active component. The medication is classified as cytostatic drugs, specialized medicines used to combat cancer, known as chemotherapy, which target cancer cells and inhibit their uncontrolled growth.

Bleomycin is versatile in cancer treatment, as it can be used alone or in combination with other cancer drugs and radiation therapy. Its proven effectiveness has led to market authorizations in various countries worldwide.

Venus Pharma GmbH CEO, Ashutosh Jain, views gaining market authorization from the Medicines and Healthcare products Regulatory Agency (MHRA) as a significant achievement. This authorization empowers the company to have a crucial impact on advancing cancer care and enhancing the lives of patients dealing with this formidable disease.

Venus Remedies takes pride in its 15 global market authorizations (MAs) for Bleomycin products. In its commitment to increasing Bleomycin's availability, the company has submitted sixteen additional applications to Ministries of Health (MOHs) worldwide. These efforts have resulted in 15 successful registrations for this drug across diverse regions, encompassing Africa, Asia, the Middle East, the Commonwealth of Independent States (CIS), North America, and South America.

"We remain dedicated to enhancing healthcare solutions and are committed to pursuing additional authorizations to reach even more patients in need," said Saransh Chaudhary, CEO, Venus Medicines Research Center.